Small cell carcinoma of the prostate

Nature Reviews Urology

Volumn 11, Issue 4, 2014, Pages 213-219

  Nadal, Rosa ^a   Schweizer, Michael ^a   Kryvenko, Oleksandr N ^b   Epstein, Jonathan I ^c   Eisenberger, Mario A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CLINICAL FEATURE; DECISION MAKING; HUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SMALL CELL CARCINOMA; WORK;

CARCINOMA, SMALL CELL; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84901192115     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.21     Document Type: Review

References (76)

1. di Sant'Agnese, P. A. & Cockett, A. T. Neuroendocrine differentiation in prostatic malignancy. Cancer 78, 357-361 (1996). (Pubitemid 26234584)
2. di Sant'Agnese, P. A. Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann. Oncol. 12 (Suppl. 2), S135-S140 (2001). (Pubitemid 33069703)
3. Casella, R. et al. Focal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsies. J. Urol. 160, 406-410 (1998).
4. Aprikian, A. G., Cordon-Cardo, C., Fair, W. R. & Reuter, V. E. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer 71, 3952-3965 (1993). (Pubitemid 23172976)
5. Cohen, R. J., Glezerson, G. & Haffejee, Z. Neuro-endocrine cells - a new prognostic parameter in prostate cancer. Br. J. Urol. 68, 258-262 (1991).
6. Shariff, A. H. & Ather, M. H. Neuroendocrine differentiation in prostate cancer. Urology 68, 2-8 (2006). (Pubitemid 44037741)
7. Abrahamsson, P. A., Cockett, A. T. & di Sant'Agnese, P. A. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl. 8, 37-42 (1998). (Pubitemid 28347994)
8. Allen, F. J., Van Velden, D. J. & Heyns, C. F. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? Br. J. Urol. 75, 751-754 (1995).
9. Ahlgren, G. et al. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 42, 274-279 (2000). (Pubitemid 30104570)
10. Tan, M. O. et al. Prostate cancer and neuroendocrine differentiation. Int. Urol. Nephrol. 31, 75-82 (1999). (Pubitemid 29284491)
11. Cohen, M. K. et al. Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumour progression. Cancer 74, 1899-1903 (1994). (Pubitemid 24301851)
12. Ishida, E., Nakamura, M., Shimada, K., Tasaki, M. & Konishi, N. Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer. Pathobiology 76, 30-38 (2009).
13. Jeetle, S. S. et al. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch. 461, 103-107 (2012).
14. Aprikian, A. G. et al. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J. Urol. 151, 914-919 (1994).
15. Wenk, R. E., Bhagavan, B. S., Levy, R., Miller, D. & Weisburger, W. Ectopic ACTH, prostatic oat cell carcinoma, and marked hypernatraemia. Cancer 40, 773-778 (1977). (Pubitemid 8177897)
16. Miyoshi, Y. et al. Neuroendocrine differentiated small cell carcinoma presenting as recurrent prostate cancer after androgen deprivation therapy. BJU Int. 88, 982-983 (2001). (Pubitemid 34099032)
17. Tanaka, M. et al. Progression of prostate cancer to neuroendocrine cell tumour. Int. J. Urol. 8, 431-437 (2001).
18. Turbat-Herrera, E. A. et al. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study. Arch. Pathol. Lab. Med. 112, 1100-1105 (1988). (Pubitemid 18266523)
19. Shah, R. B. et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy programme. Cancer Res. 64, 9209-9216 (2004). (Pubitemid 39665537)
20. Tetu, B. et al. Small cell carcinoma of the prostate. Part I. A clinicopathologic study of 20 cases. Cancer 59, 1803-1809 (1987). (Pubitemid 17075428)
21. Yao, J. L. et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am. J. Surg. Pathol. 30, 705-712 (2006). (Pubitemid 44264995)
22. Ro, J. Y., Tetu, B., Ayala, A. G. & Ordonez, N. G. Small cell carcinoma of the prostate. II. Immunohistochemical and electron microscopic studies of 18 cases. Cancer 59, 977-982 (1987). (Pubitemid 17024655)
23. Wang, W. & Epstein, J. I. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am. J. Surg. Pathol. 32, 65-71 (2008).
24. Agoff, S. N. et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumours. Mod. Pathol. 13, 238-242 (2000). (Pubitemid 30207508)
25. Ordonez, N. G. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, and CD44S immunostaining in distinguishing epithelial pleural mesothelioma from pulmonary and nonpulmonary adenocarcinoma. Am. J. Surg. Pathol. 24, 598-606 (2000). (Pubitemid 30180755)
26. Lotan, T. L. et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod. Pathol. 24, 820-828 (2011).
27. Han, B. et al. Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma. Mod. Pathol. 22, 1176-1185 (2009).
28. Guo, C. C. et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum. Pathol. 42, 11-17 (2011).
29. Williamson, S. R. et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod. Pathol. 24, 1120-1127 (2011).
30. Scheble, V. J. et al. ERG rearrangement in small cell prostatic and lung cancer. Histopathology 56, 937-943 (2011).
31. Schelling, L. A. et al. Frequent TMPRSS2-ERG rearrangement in prostatic small cell carcinoma detected by fluorescence in situ hybridization: the superiority of fluorescence in situ hybridization over ERG immunohistochemistry. Hum. Pathol. 44, 2227-2233 (2013).
32. Evans, A. J., Humphrey, P. A., Belani, J., van der Kwast, T. H. & Srigley, J. R. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am. J. Surg. Pathol. 30, 684-693 (2006). (Pubitemid 44264993)
33. Pearse, A. G. The diffuse endocrine system and the implications of the APUD concept. Int. Surg. 64, 5-7 (1979).
34. Oesterling, J. E., Hauzeur, C. G. & Farrow, G. M. Small cell anaplastic carcinoma of the prostate: a clinical, pathological and immunohistological study of 27 patients. J. Urol. 147, 804-807 (1992).
35. Ismail, A. H., Landry, F., Aprikian, A. G. & Chevalier, S. Androgen ablation promotes neuroendocrine cell differentiation in dog and human prostate. Prostate 51, 117-125 (2002).
36. Wright, M. E., Tsai, M. J. & Aebersold, R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Mol. Endocrinol. 17, 1726-1737 (2003). (Pubitemid 37072290)
37. Yuan, T. C. et al. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocr. Relat. Cancer 13, 151-167 (2006).
38. Mosquera, J. M. et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1-10 (2013).
39. Spiess, P. E. et al. Treatment outcomes of small cell carcinoma of the prostate: a single-centre study. Cancer 110, 1729-1737 (2007). (Pubitemid 47557297)
40. Helpap, B., Kollermann, J. & Oehler, U. Neuroendocrine differentiation in prostatic carcinomas: histogenesis, biology, clinical relevance, and future therapeutical perspectives. Urol. Int. 62, 133-138 (1999). (Pubitemid 29473966)
41. Bonkhoff, H. & Remberger, K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28, 98-106 (1996). (Pubitemid 26066247)
42. Stratton, M., Evans, D. J. & Lampert, I. A. Prostatic adenocarcinoma evolving into carcinoid: selective effect of hormonal treatment? J. Clin. Pathol. 39, 750-756 (1986).
43. Burchardt, T. et al. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J. Urol. 162, 1800-1805 (1999).
44. Scheble, V. J. et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumour. Mod. Pathol. 23, 1061-1067 (2010).
45. Tomlins, S. A. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310, 644-648 (2005). (Pubitemid 41528150)
46. Lapuk, A. V. et al. From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer. J. Pathol. 227, 286-297 (2012).
47. Hansel, D. E. et al. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate 69, 603-609 (2009).
48. Beltran, H. et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov. 1, 487-495 (2011).
49. Clegg, N. et al. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 55, 55-64 (2003). (Pubitemid 36397745)
50. Tzelepi, V. et al. Modeling a lethal prostate cancer variant with small-cell carcinoma features. Clin. Cancer Res. 18, 666-677 (2012).
51. Palmgren, J. S., Karavadia, S. S. & Wakefield, M. R. Unusual and underappreciated: small cell carcinoma of the prostate. Semin. Oncol. 34, 22-29 (2007). (Pubitemid 46161758)
52. Abrahamsson, P. A. Neuroendocrine cells in tumour growth of the prostate. Endocr. Relat. Cancer 6, 503-519 (1999).
53. Alshaikh, O. M., Al-Mahfouz, A. A., Al-Hindi, H., Mahfouz, A. B. & Alzahrani, A. S. Unusual cause of ectopic secretion of adrenocorticotropic hormone: Cushing syndrome attributable to small cell prostate cancer. Endocr. Pract. 16, 249-254 (2010).
54. Aparicio, A. M. et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res. 19, 3621-3630 (2013).
55. Flechon, A. et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumour Group (GETUG) P01 trial. Ann. Oncol. 22, 2476-2481 (2011).
56. Loriot, Y. et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann. Oncol. 20, 703-708 (2009).
57. Culine, S. et al. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J. Urol. 178, 844-848 (2007).
58. McCutcheon, I. E., Eng, D. Y. & Logothetis, C. J. Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment. Cancer 86, 2301-2311 (1999). (Pubitemid 30010371)
59. Cussenot, O., Villette, J. M., Cochand-Priollet, B. & Berthon, P. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumours. Prostate Suppl. 8, 43-51 (1998). (Pubitemid 28347995)
60. Heinrich, E. et al. Neuroendocrine tumour cells in prostate cancer: evaluation of the neurosecretory products 5-hydroxytryptamine, bombesin, and gastrin - impact on angiogenesis and clinical follow-up. Prostate 71, 1752-1758 (2011).
61. Ferrero-Pous, M., Hersant, A. M., Pecking, A., Bresard-Leroy, M. & Pichon, M. F. Serum chromogranin: A in advanced prostate cancer. BJU Int. 88, 790-796 (2001).
62. Amato, R. J. et al. Chemotherapy for small cell carcinoma of prostatic origin. J. Urol. 147, 935-937 (1992).
63. Hindson, D. A., Knight, L. L. & Ocker, J. M. Small-cell carcinoma of prostate. Transient complete remission with chemotherapy. Urology 26, 182-184 (1985). (Pubitemid 17067757)
64. Steineck, G. et al. Cytotoxic treatment of aggressive prostate tumours with or without neuroendocrine elements. Acta Oncol. 41, 668-674 (2002). (Pubitemid 36106212)
65. Papandreou, C. N. et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J. Clin. Oncol. 20, 3072-3080 (2002).
66. Deorah, S., Rao, M. B., Raman, R., Gaitonde, K. & Donovan, J. F. Survival of patients with small cell carcinoma of the prostate during 1973-2003: a population-based study. BJU Int. 109, 824-830 (2012).
67. Bolton, D. M., Chiu, S. T., Clarke, S. & Angus, D. Primary small cell carcinoma of the prostate: unusual modes of presentation. Aust. N. Z. J. Surg. 64, 91-94 (1994).
68. Kim, K. H., Kim, Y. B., Lee, J. K., Kim, Y. J. & Jung, T. Y. Pathologic results of radical prostatectomies in patients with simultaneous atypical small acinar proliferation and prostate cancer. Korean J. Urol. 51, 398-402 (2010).
69. Sule-Suso, J. & Brunt, A. M. Small cell carcinoma of the prostate. Br. J. Radiol. 65, 726-728 (1992).
70. NCC guidelines Index: Version 2.2013. Prostate Cancer [online], http://www.nccn.org/professionals/physician-gls/pdf/prostate.pdf (2013).
71. Auperin, A. et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N. Engl. J. Med. 341, 476-484 (1999). (Pubitemid 29372887)
72. Rubenstein, J. H. et al. Small cell anaplastic carcinoma of the prostate: seven new cases, review of the literature, and discussion of a therapeutic strategy. Am. J. Clin. Oncol. 20, 376-380 (1997). (Pubitemid 27329571)
73. Moore, S. R., Reinberg, Y. & Zhang, G. Small cell carcinoma of prostate: effectiveness of hormonal versus chemotherapy. Urology 39, 411-416 (1992).
74. NCC guidelines Index: Version 2.2013. Adult cancer pain [online], http://www.nccn.org/professionals/physician-gls/pdf/pain.pdf (2013).
75. Janssen, A. & Moedema, R. H. Mitosis as an anti-cancer target. Oncogene 30, 2799-2809 (2011).
76. Stein, M. E. et al. Small cell (neuroendocrine) carcinoma of the prostate: aetiology, diagnosis, prognosis, and therapeutic implications - a retrospective study of 30 patients from the rare cancer network. Am. J. Med. Sci. 336, 478-488 (2008).